NEXMED
Medical calculator · educational

Mounjaro Calculator (tirzepatide)

Dose escalation schedule, BMI eligibility check, estimated weight loss and dose conversion (clicks / ml) for Mounjaro (tirzepatide).

At a glance: Mounjaro (tirzepatide)

Active substance
tirzepatide
Drug class
dual GIP and GLP-1 receptor agonist
How it is given
subcutaneous injection, once a week
Maximum dose
15 mg
Dose escalation
start at 2.5 mg, then +2.5 mg every 4 weeks or more
Average weight loss
~15% (5 mg) to ~20.9% (15 mg) at 72 weeks (SURMOUNT-1)
KwikPen
1 full dose = 60 clicks = 0.6 ml

A strictly educational, indicative tool. It does not replace medical advice and does not give dosing instructions. Mounjaro (tirzepatide) is a prescription medicine: only the prescribing doctor decides eligibility and dose.

Weight-related conditions
Body mass index
32.9Obesity class I

Potentially eligible under EMA criteria

Indicative criteria: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition. The final decision is your doctor's.

BMI does not distinguish muscle from fat and has limitations (athletes, older adults, pregnancy).

Data from the SURMOUNT-1 trial

In the SURMOUNT-1 trial (72 weeks), adults without diabetes lost on average about 15% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) of their starting body weight.

About Mounjaro treatment

How Mounjaro works

Tirzepatide is the first dual agonist: it acts on the receptors of two gut hormones at once, GIP and GLP-1. This combined action reduces appetite, increases fullness, slows stomach emptying and improves blood sugar control. The dual effect explains why, in trials, average weight loss is greater than with GLP-1-only agonists.

How fast do you lose weight on Mounjaro?

As with every therapy in this class, the effect builds up over time and depends on the maintenance dose you reach. As a rough guide, based on the SURMOUNT-1 trial (72 weeks):

  • Weeks 1–4 (2.5 mg): starting dose with little effect on weight; its role is to let your body adjust.
  • About 5% of body weight: often around weeks 12–16.
  • About 15%: towards weeks 40–50, depending on the dose.
  • Up to about 20–21%: at 72 weeks (around 17 months), on the higher doses (10–15 mg).
  • During the active phase, healthy weight loss is roughly 0.5–1 kg (1–2 lb) a week. Higher doses tend to give bigger results, but also more digestive side effects.

What to expect during treatment

The most common side effects are digestive (nausea, diarrhoea, constipation, bloating), usually mild and temporary, especially after each dose increase. Gradual escalation (2.5 mg steps at least 4 weeks apart), smaller meals and good hydration help. Tell your doctor if symptoms are severe or persistent.

Nutrition matters as much as the medicine

These treatments reduce appetite, so you will eat less, which makes the quality of every meal even more important. A good diet prevents nutritional deficiencies, protects muscle mass and improves digestive tolerance. Ideally, your eating plan is put together with a doctor or registered dietitian, rather than simply eating smaller portions.

Protein: protect your muscle mass

With rapid weight loss there is a risk of losing muscle as well as fat. Eating enough protein, spread across every meal, helps preserve muscle and keeps you full for longer.

  • As a guide, about 1.2–1.6 g of protein per kg of ideal body weight per day (individualised by your doctor or dietitian).
  • Spread protein across every meal, not just dinner.
  • Good sources: eggs, lean meat, fish, dairy, legumes, tofu.
  • Combine it with strength training to maintain muscle.

Fibre: fullness, blood sugar and digestion

Fibre keeps you full for longer, softens blood sugar spikes and helps prevent constipation, a common side effect of these treatments.

  • Increase fibre gradually and drink enough water to avoid bloating.
  • Aim for about 25–30 g of fibre a day from a variety of foods.
  • Sources: vegetables, fruit, legumes, wholegrains, seeds.

Hydration and habits that reduce nausea

Drink water steadily throughout the day, since dehydration makes nausea and constipation worse. Choose small, frequent meals, eat slowly and stop at the first sign of fullness. Limit very fatty, fried and ultra-processed foods and concentrated sweets, as they make nausea worse. Keep alcohol moderate: it adds empty calories and irritates the stomach.

Keeping the weight off long term

Because obesity is a chronic disease, stopping treatment often leads to regaining some of the weight as appetite returns. Lasting results require long-term treatment alongside a balanced diet and physical activity.

Who can use it

Mounjaro is used for type 2 diabetes and, in the EU and UK, for chronic weight management (as a guide, BMI of 30 or more, or 27 or more with a weight-related condition). In the US, the weight-management version of tirzepatide is Zepbound. It must not be used during pregnancy and has contraindications (for example a history of medullary thyroid carcinoma or MEN2 syndrome, or pancreatitis). Only your doctor can decide whether it is right for you and at what dose.

Mounjaro: frequently asked questions

What is the Mounjaro dose schedule?+

Treatment starts at 2.5 mg once a week for 4 weeks (the starting dose), then increases by 2.5 mg steps at least every 4 weeks, depending on response and tolerability, up to a maximum of 15 mg a week.

How much weight can you lose on Mounjaro?+

In the SURMOUNT-1 trial, average weight loss at 72 weeks was about 15% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg in adults without diabetes. Individual results vary.

How many clicks are in a Mounjaro KwikPen dose?+

For reference, one full KwikPen dose corresponds to 60 clicks and a volume of 0.6 ml (0.01 ml per click). This is an informational unit conversion, not dosing instructions.

Is Mounjaro the same as Zepbound?+

Both contain tirzepatide. In the United States, tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management. In the EU and UK, Mounjaro is approved for both uses.

Who is this calculator for?+

It is an educational tool for patients and healthcare professionals who want to understand the dose escalation schedule, the eligibility criteria and the average results seen in clinical trials. It is not a medical device and does not give personalised recommendations.

Are the projected results guaranteed?+

No. The figures are averages from clinical trials. Your individual result depends on diet, physical activity, adherence to treatment, dose and medical factors. Some people lose more weight, others less.

Why is gradual dose escalation important?+

Increasing the dose step by step reduces digestive side effects (nausea, vomiting, diarrhoea). Your doctor may slow the pace if you are not tolerating it well. Do not rush and do not skip steps.

Other calculators

Sources and limitations

The dose escalation schedule follows the summary of product characteristics (SmPC/EMA). Average results come from the SURMOUNT-1 trial. The eligibility criteria (BMI ≥ 30, or ≥ 27 with weight-related conditions) are indicative.

This calculator does not diagnose or prescribe treatment. For any medical decision, talk to your doctor and read the approved patient leaflet.EMA

Content last reviewed: 19 August 2026.